All In Biotech

Drug Trial Radar · NCT07097935

Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma

A Phase Ib/II Clinical Study Evaluating the Safety, Efficacy, Tolerability, and Pharmacokinetics of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Jul 10, 2025

Primary completion

Jul 10, 2027

Study completion Jul 10, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, Phase Ib/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10516 in combination with lenvatinib in patients with advanced clear cell renal cell carcinoma (ccRCC) who have progressed after receiving at least one prior line of systemic therapy. The study comprises two distinct phases: a dose exploration phase and a proof-of-concept phase.

Conditions

  • Advanced Clear Cell Renal Cell Carcinoma

Interventions

  • HS-10516 + LenvatinibDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: MTD or RP2DTime frame: Up to 3 months
  2. Phase II: Objective Response Rate (ORR)Time frame: Up to 12 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.